Missible oil containing saflufenacil and clethodim and preparation method thereof

Abstract

The invention provides missible oil containing saflufenacil and clethodim and a preparation method of the missible oil, and the missible oil comprises the following components in percentage by mass: 5%-60% of the clethodim, 1%-20% of the saflufenacil, 10%-20% of an emulsifier, 5%-20% of a synergist, 10%-35% of a cosolvent and the balance of a solvent. By adjusting the combination of the solvent and the auxiliary agent, the stability problem of saflufenacil crystals and clethodim separated out by diluting missible oil with water is solved while the saflufenacil is ensured to be dissolved, the combination has no influence on the stability of the clethodim basically, the decomposition rate of the clethodim is stably controlled within 8.5%, and the stability of the clethodim is greatly improved. It can be guaranteed that no raw pesticide is separated out of pesticide liquid under the use concentration of missible oil, the risk that a spray head is blocked is avoided, and the pesticide effect of saflufenacil can be achieved easily. The composition improves the stability of the effective components, enhances the formula effect, and can ensure excellent pesticide effect. The improvement of the clethodim stability also prolongs the shelf life of the preparation.

Description

Technical Field

[0001] The invention relates to the technical field of pesticides, and in particular to an emulsifiable concentrate containing saflufenacil and clethodim and a preparation method thereof. Background Art

[0002] After the harvest, the farmland enters the fallow period, during which weed control is required. Glyphosate is mainly used for weeding in non-cultivated land and during the fallow period of farmland. As glyphosate-resistant weeds increase year by year, glyphosate-resistant weeds need secondary weeding after spraying glyphosate. Glyphosate alone can no longer meet the weed control requirements for resistant weeds. At the same time, secondary weeding has high requirements for the herbicide composition, requiring fast effect after application, excellent weed control effect, short half-life in the soil, and no impact on the cultivation of the next crop.

[0003] Saflufenacil (N′-{2-chloro-4-fluoro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]benzoyl}-N-isopropyl-N-methanesulfonamide) is a protoporphyrinogen oxidase inhibitor that can be absorbed by the root and seedling tissues of plants. After the plant absorbs the agent, the chloroplast pigment turns white, the tissue necrotizes, and the growth is finally inhibited until the plant dies. It can be used as a lethal herbicide to effectively control a variety of broadleaf weeds, including weeds that are resistant to glyphosate, ALS inhibitors and triazine inhibitors.

[0004] Clethodim ((E)-2-[1-(3-chloroallyloxyimino)propyl]-5-[2-(ethylthio)propyl]-3-hydroxycyclohex-2-enone) is a systemic stem and leaf treatment agent. After stem and leaf treatment, it is rapidly absorbed by the leaves and transmitted to the meristem and roots, destroying cell division and inhibiting the activity of plant meristems. Within 1 to 3 weeks after application, the plants turn green and necrotic, and then the leaves dry up and die. Clethodim is suitable for broad-leaved fields such as soybeans, rapeseed, tobacco, cotton, peanuts, and flax. It can prevent and control more than 30 kinds of grass weeds such as barnyard grass, hard grass, crabgrass, wild oats, foxtail grass, foxtail grass, goosegrass, and bluegrass. It is easily decomposed in the soil, has low soil activity, a short duration, and has no effect on subsequent crops.

[0005] Clethodim has the advantages of high efficiency, safety, high selectivity, and no pollution. It can prevent and control grass (pointed leaf) weeds in broad-leaved crop fields such as soybeans, rapeseed, cotton, and peanuts. It can effectively prevent and control grass weeds such as wild oats, crabgrass, foxtail grass, goosegrass, bluegrass, and hard grass. Clethodim has a short half-life in the soil and is easily decomposed into safe substances in the soil, so it is very safe for subsequent crops and the environment. With the continuous development of weeds resistant to glyphosate, the use of clethodim mixed with glyphosate can be used as a means to deal with and resist glyphosate resistance. Take goosegrass as an example. Its root system is well-developed and deep, and its drought resistance and growth ability are particularly strong. Glyphosate is generally used for prevention and control. Due to the resistance caused by large-scale and long-term use of glyphosate, the prevention effect is not good. Clethodim is effective in preventing goosegrass of the grass family. Clethodim mixed with glyphosate for spraying has become a "special weapon" for preventing and controlling goosegrass.

[0006] When saflufenacil is combined with clethodim, it can kill grass weeds and broadleaf weeds, and is highly effective against weeds resistant to glyphosate. However, due to the difference in solubility between the two, saflufenacil is not easy to dissolve. It can be dissolved using a strong polar solvent, but when the product is diluted to the concentration used, the original drug crystals will precipitate, clogging the nozzle and making it inconvenient to use, and affecting the efficacy of the drug. In the process of dissolving saflufenacil, the choice of solvent will also affect the stability of clethodim, resulting in a high decomposition rate of clethodim and poor efficacy. This means that there is currently no stable formulation for the combination of saflufenacil and clethodim.

[0007] How to solve the stability problem of sethoxydim and avoid the solvent that dissolves saflufenacil causing an increase in the decomposition rate of sethoxydim is a current industry challenge. Summary of the invention

[0008] In view of this, the technical problem to be solved by the present invention is to provide an emulsifiable concentrate containing saflufenacil and clethodim and a preparation method thereof, which has high stability.

[0009] To achieve the above object, the present invention provides an emulsifiable concentrate containing saflufenacil and clethodim, which comprises, by mass percentage:

[0010] Clethodim 5%-60%, saflufenacil 1%-20%, emulsifier 10%-20%, synergist 5%-20%, co-solvent 10%-35%, solvent replenishment 100%.

[0011] The present invention uses clethodim and saflufenacil as active ingredients. The mass ratio of clethodim to saflufenacil is preferably 5-60:1-20, more preferably 12-48:2-5, including but not limited to 48:2, 12:5, 24:2.5, 24:5, 36:2.5, and most preferably 24:2.5.

[0012] The mass content of clethodim in the emulsifiable concentrate is preferably 5% to 60%, more preferably 12% to 48%, including but not limited to 12%, 24%, 36%, and 48%.

[0013] The mass content of saflufenacil in the emulsifiable concentrate is preferably 1% to 20%, more preferably 2% to 5%, including but not limited to 2%, 2.5%, and 5%.

[0014] Most preferably, in the emulsifiable concentrate, the mass content of clethodim is 24%, and the mass content of saflufenacil is 2.5%.

[0015] The test results show that the emulsifiable concentrate prepared with the above active ingredient content has higher stability than other contents.

[0016] The mass content of the emulsifier in the emulsifiable concentrate is preferably 10% to 20%, more preferably 10% to 13%.

[0017] The emulsifier is preferably one or more of calcium dodecylbenzene sulfonate, polyoxyethylene styrylphenol ether, polyoxyethylene castor oil ether, PR500M, polyoxyethylene styrylphenol polyoxypropylene ether, Tween 80, and polyoxyethylene ether sulfonate, and more preferably any two selected from calcium dodecylbenzene sulfonate, polyoxyethylene styrylphenol ether, polyoxyethylene castor oil ether, PR500M, polyoxyethylene styrylphenol polyoxypropylene ether, Tween 80, and polyoxyethylene ether sulfonate.

[0018] Further preferably, the emulsifier is a composite emulsifier of a first emulsifier and a second emulsifier. The first emulsifier is preferably calcium dodecylbenzene sulfonate, and the second emulsifier is preferably castor oil polyoxyethylene ether or Tween 80. The second emulsifier is more preferably castor oil polyoxyethylene ether.

[0019] The mass ratio of the first emulsifier to the second emulsifier is preferably 1:1 to 1:7, more preferably 1:2 to 1:7, further preferably 1:3 to 1:6, and most preferably 3:10 to 2:11.

[0020] In some specific embodiments of the present invention, the emulsifier is a composite emulsifier of calcium dodecylbenzene sulfonate and castor oil polyoxyethylene ether.

[0021] The mass content of the calcium dodecylbenzene sulfonate in the emulsifiable concentrate is preferably 2% to 3%, and the mass content of the castor oil polyoxyethylene ether in the emulsifiable concentrate is preferably 10% to 11%.

[0022] In some specific embodiments of the present invention, the emulsifier is a composite emulsifier of 2% calcium dodecylbenzene sulfonate and 11% castor oil polyoxyethylene ether.

[0023] In some specific embodiments of the present invention, the emulsifier is a composite emulsifier of 3% calcium dodecylbenzene sulfonate and 10% castor oil polyoxyethylene ether.

[0024] The test results show that when calcium dodecylbenzene sulfonate and castor oil polyoxyethylene ether are used as emulsifiers, especially when the content of calcium dodecylbenzene sulfonate is 2% and the content of castor oil polyoxyethylene ether is 11%, the prepared emulsifiable concentrate has higher water adaptability and stability, and the decomposition rate of clethodim is the lowest.

[0025] The mass content of the synergist in the emulsifiable concentrate is preferably 5% to 20%, more preferably 6% to 7%.

[0026] The synergist is preferably one or more of fatty alcohol polyoxyethylene ether, sodium diisooctyl sulfosuccinate, and ethoxy-modified polytrisiloxane, and more preferably any two thereof.

[0027] Furthermore, the synergist is a compound synergist of a first synergist and a second synergist. The first synergist is preferably fatty alcohol polyoxyethylene ether or ethoxy-modified polytrisiloxane, more preferably fatty alcohol polyoxyethylene ether; and the second synergist is preferably sodium dioctyl sulfosuccinate.

[0028] The mass ratio of the first synergist to the second synergist is preferably 1:1 to 1:4, more preferably 1:1 to 1:2.5.

[0029] In some specific embodiments of the present invention, the synergist is fatty alcohol polyoxyethylene ether and sodium diisooctyl sulfosuccinate.

[0030] The mass content of the fatty alcohol polyoxyethylene ether in the emulsifiable concentrate is preferably 2% to 3%, and the mass content of the sodium diisooctyl sulfosuccinate in the emulsifiable concentrate is preferably 3% to 5%.

[0031] In some specific embodiments of the present invention, the synergist is 2% of fatty alcohol polyoxyethylene ether and 5% of sodium diisooctyl sulfosuccinate.

[0032] In some specific embodiments of the present invention, the synergist is 3% of fatty alcohol polyoxyethylene ether and 3% of sodium diisooctyl sulfosuccinate.

[0033] Clethodim needs to be treated with a synergist to fully exert its efficacy, but the synergist will affect the stability of Clethodim. The test results show that when the synergist is fatty alcohol polyoxyethylene ether and sodium diisooctyl sulfosuccinate, the synergist can play the best synergistic role and has no effect on the decomposition rate of Clethodim. It can optimize the comprehensive performance of the emulsifiable concentrate product, especially the stability, and ensure the efficacy of the product.

[0034] Especially when the content of fatty alcohol polyoxyethylene ether is 2% and the content of sodium diisooctyl sulfosuccinate is 5%, the prepared emulsifiable concentrate has higher water quality adaptability and stability, and the decomposition rate of clethodim is the lowest.

[0035] The mass content of the co-solvent in the emulsifiable concentrate is preferably 10% to 35%, more preferably 25% to 30%.

[0036] The co-solvent is preferably one or more of cyclohexanone, N,N-dimethylpyrrolidone, isophorone, N,N-dimethyldecylamide, diethylene glycol ethyl ether, N,N-dimethylformamide, N,N-dimethylacetamide, and dimethyl sulfoxide, and more preferably any two selected therefrom.

[0037] Furthermore, the cosolvent is a composite cosolvent of a first cosolvent and a second cosolvent. The first cosolvent is preferably cyclohexanone or isophorone, more preferably isophorone; and the second cosolvent is preferably N,N-dimethyldecylamide.

[0038] The mass ratio of the first co-solvent to the second co-solvent is preferably 1.5:1 to 1:5, more preferably 1.5:1 to 1:4, including but not limited to 1.5:1, 1:2, 1:4, more preferably 1:4.

[0039] In some specific embodiments of the present invention, the co-solvent is cyclohexanone and N,N-dimethyldecylamide.

[0040] The mass content of the cyclohexanone in the emulsifiable concentrate is preferably 5% to 15%, and the mass content of the N,N-dimethyldecylamide in the emulsifiable concentrate is preferably 10% to 20%.

[0041] In some specific embodiments of the present invention, the co-solvent is 5% cyclohexanone and 20% N,N-dimethyldecylamide.

[0042] In some specific embodiments of the present invention, the co-solvent is 15% cyclohexanone and 10% N,N-dimethyldecylamide.

[0043] In some specific embodiments of the present invention, the co-solvent is isophorone and N,N-dimethyldecylamide.

[0044] The mass content of isophorone in the emulsifiable concentrate is preferably 5% to 10%, and the mass content of N,N-dimethyldecylamide in the emulsifiable concentrate is preferably 20%.

[0045] In some specific embodiments of the present invention, the co-solvent is 5% isophorone and 20% N,N-dimethyldecylamide.

[0046] In some specific embodiments of the present invention, the co-solvent is 10% isophorone and 20% N,N-dimethyldecylamide.

[0047] The experimental results show that when isophorone and N,N-dimethyldecylamide are used as co-solvents, the solvent combination of isophorone and N,N-dimethyldecylamide solves the solubility problem of saflufenacil. The prepared emulsifiable concentrate has qualified low-temperature stability and the emulsion has no crystallization, which is beneficial to the efficacy of saflufenacil. This combination has no effect on the stability of sethoxydim.

[0048] Especially when the isophorone content is 5% and the N,N-dimethyldecylamide content is 20%, the prepared emulsifiable concentrate has higher water adaptability and stability, and the decomposition rate of clethodim is the lowest.

[0049] The emulsifiable concentrate provided by the invention also comprises a residual amount of solvent.

[0050] The solvent is preferably one or more of solvent oil 150#, solvent oil 200#, xylene, methyl oleate, and propylene carbonate, more preferably solvent oil 200# or methyl oleate, and further preferably solvent oil 200#.

[0051] The test results show that the use of solvent oil 200# can achieve higher water quality adaptability and stability, and the decomposition rate of clethodim is the lowest.

[0052] The present invention has no particular limitation on the preparation method of the emulsifiable concentrate, and the emulsifiable concentrate can be prepared according to methods well known to those skilled in the art.

[0053] Optionally, the present invention provides a method for preparing the above-mentioned emulsifiable concentrate containing saflufenacil and clethodim, comprising the following steps:

[0054] S1) mixing the solvent and the cosolvent, then adding saflufenacil and stirring to dissolve;

[0055] S2) adding an emulsifier and a synergist to the system obtained in S1), and stirring to obtain a homogeneous solution system;

[0056] S3) mixing and dissolving clethodim and the above homogeneous solution system to obtain a homogeneous mixture.

[0057] The temperature during the stirring and dissolving stage in step S1) is preferably 20-40° C., and the stirring time is preferably 30-40 min.

[0058] In the step S2), when the emulsifier and synergist are added, the temperature is preferably 25-40° C., and the stirring time is preferably 30-40 min.

[0059] In the mixed dissolution stage of step S3), the temperature is preferably 20-40° C., and stirring is preferably used to promote dissolution. The stirring time is preferably 30-40 minutes, until clethodim is dissolved.

[0060] The present invention optimizes the process conditions according to the characteristics of clethodim. By adjusting the order of adding the auxiliary agents, the water is adsorbed by the auxiliary agent micelles after the emulsifier and the synergist are added, and the free water content is reduced. When clethodim is added at this time, clethodim is difficult to contact with water, thereby avoiding the hydrolysis reaction and reducing the decomposition rate of clethodim. By adjusting the temperature control and the order of addition, the decomposition rate of clethodim is controlled, and the influence of the processing process on clethodim is avoided.

[0061] Compared with the prior art, the present invention provides an emulsifiable concentrate containing saflufenacil and clethodim, which comprises, by mass percentage, 5% to 60% clethodim, 1% to 20% saflufenacil, 10% to 20% emulsifier, 5% to 20% synergist, 10% to 35% cosolvent, and the solvent is supplemented to 100%.

[0062] The present invention solves the problem of the precipitation of saflufenacil crystals and the stability of clethodim when the emulsifiable concentrate is diluted with water and the stability of clethodim by adjusting the solvent and auxiliary agent combination while ensuring the dissolution of saflufenacil. This combination has basically no effect on the stability of clethodim, and the decomposition rate of clethodim is stably controlled within 8.5%, which can ensure that the emulsifiable concentrate has no original drug precipitation at the concentration used, and there is no risk of clogging the nozzle, which is conducive to the efficacy of saflufenacil. This combination simultaneously achieves the improvement of the stability of the active ingredient and the synergistic effect of the formula, and can ensure excellent efficacy performance. The improvement of the stability of clethodim also extends the shelf life of the preparation. DETAILED DESCRIPTION

[0063] To further illustrate the present invention, the emulsifiable concentrate containing saflufenacil and clethodim provided by the present invention and the preparation method thereof are described in detail below with reference to the examples.

[0064] Examples 1-8

[0065] According to the ratio in Table 1, prepare emulsifiable concentrate, and the preparation method is as follows:

[0066] (1) adding a solvent and a co-solvent, mixing, adding saflufenacil, heating to 20-40° C., stirring for 30-40 minutes to dissolve;

[0067] (2) Control the temperature at 25-40° C., add the emulsifier and synergist, and stir thoroughly for 30-40 minutes to obtain a homogeneous solution system;

[0068] (3) adding clethodim, maintaining the temperature at 20-40° C. and stirring for 30-40 min to dissolve to obtain a homogeneous mixture;

[0069] Comparative Example 1-2

[0070] The preparation method is the same as that of Examples 1-8, and the distribution ratio of each group is shown in Table 1.

[0071] Table 1 Ratio of raw materials in Examples 1-8 and Comparative Examples 1-2 (mass percentage)

[0072]

[0073]

[0074] The properties of the emulsifiable concentrates prepared in Examples 1-8 and Comparative Examples 1-2 were tested, and the results are shown in Table 2 below.

[0075] Among them, the emulsion stability is tested according to the GB / T1603-1979 test method. The cold storage stability is tested according to GB / T19137-2003, and the hot storage stability is tested according to GB / T19136-2021.

[0076] The evaluation criteria for emulsification and dispersibility are as follows: put 95mL of standard water in a 100mL measuring cylinder, add 5mL of emulsifiable concentrate, and observe its dispersion state. Excellent: it can automatically disperse into a milky white cloud with blue fluorescence, and automatically turn upward, with basically no visible particles, and a layer of blue emulsion film on the wall; Good: most of the emulsifiable concentrate automatically disperses into a milky white cloud, with a small amount of visible particles or a small amount of floating oil; Acceptable: it can disperse into a milky white cloud. Poor: it does not disperse, and it sinks as oil droplets or particles.

[0077] Table 2 Performance of saflufenacil and clethodim emulsifiable concentrates prepared in Examples 1-8 and Comparative Examples 1-2

[0078]

[0079] It can be seen from the data in Table 2 that the emulsifiable concentrate product prepared in the examples of the present application has relatively stable quality before and after heat storage, maintains excellent water quality adaptability, emulsion stability, and high stability of clethodim, and its performance is better than that of comparative examples 1-2.

[0080] Comparative Example 3

[0081] On the basis of Example 4, the emulsifier was replaced with 13% of styrylphenol polyoxyethylene polyoxypropylene ether, and the other components and contents remained unchanged to prepare an emulsifiable concentrate. The preparation method was the same as the above example.

[0082] Comparative Example 4

[0083] On the basis of Example 4, the synergist was replaced with 7% alkyl polyglycoside (APG), and the other components and contents remained unchanged to prepare an emulsifiable concentrate. The preparation method was the same as the above example.

[0084] Comparative Example 5

[0085] On the basis of Example 4, the co-solvent was replaced with 25% benzyl alcohol, and the other components and contents remained unchanged to prepare an emulsifiable concentrate. The preparation method was the same as the above example.

[0086] Comparative Example 6

[0087] On the basis of Example 4, the solvent was replaced with solvent oil 100#, and the other components and contents remained unchanged to prepare emulsifiable concentrate. The preparation method was the same as the above example.

[0088] The properties of the emulsifiable concentrates prepared in Comparative Examples 3-6 were tested, and the results are shown in Table 3 below.

[0089] Table 3 Performance of saflufenacil and clethodim emulsifiable concentrates prepared in Comparative Examples 3-6

[0090]

[0091] Comparative Examples 3-6 prove through single factor control experiments that the compounded emulsifier, synergist, cosolvent, and specific solvent in the present invention play a good role in improving the stability of emulsifiable concentrate.

[0092] Field test example: Efficacy test on weeds in fallow fields

[0093] This experiment was arranged to be carried out in Weifang City, Shandong Province. The experiment was carried out on fallow farmland, and the experimental plot was divided into multiple small areas, each of which was blocked by ridges.

[0094] The experimental plots were randomly arranged, and the experiment set up blank control treatment and drug treatment, with a total of 4 groups of treatments, and each treatment was repeated 3 times. The 4 treatments were: Treatment 1: clean water spray, blank control; Treatment 2: Examples 4, 5, 8 and Comparative Examples 1, 2; Treatment 3: Clethodim 24% EC; Treatment 4: Safensulfuron 70% WG.

[0095] The pesticide was applied once with a Gongnong-16 backpack manual sprayer. 450 kg of liquid was prepared according to the dosage of the preparation per hectare, and the liquid volume was converted to the plot for uniform spraying. The weather was good during the test, with an average daily temperature of 25-35.0℃. There was no rain on the day of application.

[0096] Thirty days after application, the control effect of each treatment on the fresh weight of weeds was investigated. The results are shown in Table 4.

[0097] Method for investigating the fresh weight control effect of weeds:

[0098] 30 days after application, 4 points were randomly selected from each plot, with a depth of 0.25 m 2 , remove weeds, classify them and weigh their fresh weight, and calculate the weed control effect by fresh weight.

[0099]

[0100] Table 4 Results of the efficacy test of each treatment agent on annual weeds in fallow land

[0101]

[0102] It can be seen from the test results in Table 4 that the combination of safensulfuron and clethodim has a good control effect on grass weeds and broad-leaved weeds in fallow period farmland. Compared with the control agent, Examples 4, 5, 8 and Comparative Examples 1 and 2 show obvious synergistic effects. Specifically, in the comparison of Treatment 2 and the control agent Treatment 3 clethodim 24% EC, the two-element combination reduces the amount of application and increases the efficacy of the malignant weeds sedge and foxtail grass that have drug resistance, achieving the effect of increasing efficiency and reducing application; and can control broad-leaved weeds. Treatment 2 is compared with the control agent Treatment 4 safensulfuron 70% WG. The two-element combination has excellent effects on the prevention and control of grass weeds sedge and foxtail grass, and also plays a synergistic role in the prevention and control of broad-leaved weeds.

[0103] From the comparison of the efficacy of each embodiment and the comparative example, it can be seen that the selection of adjuvants has an important influence on the performance of the active ingredients, and improper selection of adjuvants will affect the compounding effect of saflufenacil and clethodim.

[0104] The protective effects of Examples 4, 5 and 8 are significantly better than those of Comparative Examples 1 and 2.

[0105] The above embodiments are only used to help understand the method and core idea of ​​the present invention. It should be noted that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principles of the present invention, and these improvements and modifications also fall within the scope of protection of the claims of the present invention.

Claims

1. An emulsifiable concentrate containing saflufenacil and clethodim, characterized in that: In terms of mass percentage, it includes: Clethodim 5%-60%, saflufenacil 1%-20%, emulsifier 10%-20%, synergist 5%-20%, co-solvent 10%-35%, solvent replenishment 100%.

2. The emulsifiable concentrate containing saflufenacil and clethodim according to claim 1, characterized in that The emulsifier is selected from one or more of calcium dodecylbenzene sulfonate, polyoxyethylene styrylphenol ether, polyoxyethylene castor oil ether, PR500M, polyoxyethylene polyoxypropylene styrylphenol ether, Tween 80, and polyoxyethylene ether sulfonate.

3. The emulsifiable concentrate containing saflufenacil and clethodim according to claim 2, characterized in that: The emulsifier is a composite emulsifier of a first emulsifier and a second emulsifier; The first emulsifier is calcium dodecylbenzene sulfonate, and the second emulsifier is castor oil polyoxyethylene ether or Tween 80.

4. The emulsifiable concentrate containing saflufenacil and clethodim according to claim 1, characterized in that The synergist is selected from one or more of fatty alcohol polyoxyethylene ether, sodium diisooctyl sulfosuccinate, and ethoxy-modified polytrisiloxane.

5. The emulsifiable concentrate containing saflufenacil and clethodim according to claim 4, characterized in that: The synergist is a composite synergist of a first synergist and a second synergist; The first synergist is fatty alcohol polyoxyethylene ether or ethoxy-modified polytrisiloxane, and the second synergist is sodium diisooctyl sulfosuccinate.

6. The emulsifiable concentrate containing saflufenacil and clethodim according to claim 1, characterized in that: The co-solvent is selected from one or more of cyclohexanone, N,N-dimethylpyrrolidone, isophorone, N,N-dimethyldecylamide, diethylene glycol ethyl ether, N,N-dimethylformamide, N,N-dimethylacetamide, and dimethyl sulfoxide.

7. The emulsifiable concentrate containing saflufenacil and clethodim according to claim 6, characterized in that: The co-solvent is a composite co-solvent of a first co-solvent and a second co-solvent; The first co-solvent is cyclohexanone or isophorone, and the second co-solvent is N,N-dimethyldecylamide.

8. The emulsifiable concentrate containing saflufenacil and clethodim according to claim 1, characterized in that: The solvent is selected from one or more of solvent oil 150#, solvent oil 200#, xylene, methyl oleate, and propylene carbonate.

9. The emulsifiable concentrate containing saflufenacil and clethodim according to claim 8, characterized in that: The solvent is selected from solvent oil 200# or methyl oleate.

10. The method for preparing the emulsifiable concentrate containing saflufenacil and clethodim according to any one of claims 1 to 9, comprising the following steps: S1) mixing the solvent and the cosolvent, then adding saflufenacil and stirring to dissolve; S2) adding an emulsifier and a synergist to the system obtained in S1), and stirring to obtain a homogeneous solution system; S3) mixing and dissolving clethodim and the above homogeneous solution system to obtain a homogeneous mixture.

Images